

Recent patent applications in antiviral vaccines

Patent #	Subject	Assignee	Inventor(s)	Priority application date	Publication date
WO 200481178	A method for selecting an individual biological specimen from many specimens to generate a highly infectious stock of a human papillomavirus type.	Advanced Research & Technology Institute (Indianapolis, IN, USA)	Brown DR	3/6/2003	9/23/2004
WO 200480387	A new purified immunogenic complex comprising an antigenic molecule cross-linked to a CD91 ligand; useful in treating or preventing cancer or infectious disease or inducing an immune response against an antigenic molecule.	University of Connecticut Health Center (Farmington, CT, USA)	Srivastava PK	2/4/2003	9/23/2004
US 20040185064	A method for enhancing the immunity to infection of a pathogenic virus, comprises administering a recombinant adenovirus comprising an antigen sequence heterologous to native adenovirus; useful for preventing or treating viral or bacterial diseases.	Wang D	Wang D	11/1/2002	9/23/2004
WO 200478955	A new cell culture medium devoid of exogenous components of primary animal origin, comprising at least one exogenous growth factor of nonanimal secondary origin; useful for producing an animal or viral vaccine.	GlaxoSmithKline Biologicals (Rixensart, Belgium)	Aerts BGL, Ghislain YJM, Gonze MJ, Knott ISL, Maggetto C	3/3/2003	9/16/2004
WO 200478912	A new promoter from the avian RNA polymerase I gene useful in the preparation of recombinant negative polarity RNA viruses for making antiviral vaccines.	CNRS; Institut Pasteur; Université Paris 7-Denis-Diderot (Paris)	Massin P, Naffakh N, van der Werf S	2/28/2003	9/16/2004
WO 200478203	A vaccine comprising an attenuated infectious bronchitis virus (IBV), strain Beaudette, comprising a heterologous IBV spike gene; useful for protecting poultry against infectious bronchitis.	Akzo Nobel NV (Arnhem, the Netherlands); Institute for Animal Health (Compton, UK)	Britton P, Cavanagh D, Tarpey I	3/3/2003	9/16/2004
WO 200478977	A new nucleic acid sequence encoding a fragment of the adenovirus fiber capsid protein, comprising the C-terminal knob domain of the fiber protein; useful as a vaccine for preventing adenoviral pathogenic infection in an animal.	ABIC Ltd. (Beit Shemesh, Israel)	Fingerut E, Gallili G, Gutter B, Michael A, Pitcovski J	3/4/2003	9/16/2004
WO 200478926	A biomarker composition having antigenic markers and a carrier; useful for diagnosing or treating <i>Mycobacterium</i> , hepatitis C virus, Epstein-Barr virus and/or human immunodeficiency virus infections.	Michigan State University (E. Lansing, MI, USA)	Root-Bernstein R	2/28/2003	9/16/2004
WO 200476645	A composition comprising nucleic acid molecules encoding a cytomegalovirus (CMV) polypeptide that induces a neutralizing antibody response and/or a cell-mediated immune response; useful for inhibiting and treating human CMV infections.	University of Massachusetts (Amherst, MA, USA)	Lu S, Shen S	2/27/2003	9/10/2004
EP 1454988	A method for producing flavivirus-like particles for use as a vaccine, comprising transfecting cells with cDNA encoding flavivirus prM and/or E protein, and expressing and allowing structural proteins to form virus-like particles.	INSERM (Paris)	Bartosch B, Cosset F	3/3/2003	9/8/2004

Source: Derwent Information, Alexandria, VA. The status of each application is slightly different from country to country. For further details, contact Derwent Information, 1725 Duke Street, Suite 250, Alexandria, Va 22314. Tel: 1 (800) DERWENT (info@derwent.com).